Zhaoqiang Cui, Zhaohui Qiu, Wenli Cheng, Wei Hu, Genshan Ma, Xiaojun Cai, Yafei Jin, Yi Zhao, Liqun He, Ying Li, Peili Bu, Xiaoping Chen, Ruxing Wang, Lin Chen, Peng Dong, Liuliu Feng, Xuebin Han, Mei Hong, Yinglong Hou, Minlei Liao, Mingliang Wang, Xiaoyan Wang, Jianhong Xie, Yawei Xu, Zhenxing Wang, Kai Huang, Yongle Li, Dongsheng Li, Xiaojun Ji, Jing Huang, Jun Wang, Danhong Fang, Jian'an Wang, Lijiang Tang, Yingwu Liu, Guosheng Fu, Juan Du, Ling Wang, Mengqi Liu, Junbo Ge
There lacks real-world study with a large sample size assessing olmesartan medoxomil-amlodipine besylate (OM-AML) tablet. Therefore, this study aimed to evaluate the efficacy and safety of OM-AML tablet in patients with essential hypertension. Totally, 1341 patients from 36 medical centers with essential hypertension who took OM-AML (20/5 mg) tablet were analyzed in the current prospective, single-arm, multi-center, real-world study (SVK study). Seated systolic blood pressure (SeSBP) and seated diastolic blood pressure (SeDBP) at baseline, week (W)4 and W8 were measured...
September 4, 2023: Journal of Clinical Hypertension